LEADING THE FIELD



PLANT HEALTH CARE PLC (AIM: PHC) COMPANY OVERVIEW AND H1 TRADING STATEMENT – JULY 2021

PHC investor presentation July 2021

DISCLAIMER

This document comprises a presentation (this "Presentation") which is being supplied to you solely for your information and may not be reproduced, redistributed or passed to any other person or published in whole or in part for any purpose.

This Presentation has been prepared by and is the sole responsibility of Plant Health Care plc (the "Company"). This Presentation does not constitute an offer to sell or a solicitation of offers to buy securities of the Company. This document is not an admission document or a prospectus and persons receiving this Presentation should not subscribe for or purchase shares in the capital of the Company on the basis of the information contained within it.

This Presentation has not been approved by the London Stock Exchange, the US Securities and Exchange Commission or any state securities administrator, or by any authority which could be a competent authority for the purposes of the Prospectus Directive (2003/71/EC). No third party has independently verified any of the information contained in this Presentation.

This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities in any jurisdiction nor shall it or any part of it form the basis of or be relied on in connection with, or act as any invitation or inducement to enter into, any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information or opinions contained in this Presentation or on the completeness, accuracy or fairness of such information or opinions. No offer of shares in the capital of the Company is being or will be made in the United Kingdom in circumstances which would require a prospectus approved by the UK Financial Conduct Authority for the purposes of section 87A of the Financial Services and Markets Act 2000.

Nothing in this Presentation constitutes the giving of investment advice. Any person seeking to acquire shares in the Company should conduct their own independent investigation and analysis of the Company and of the information contained in this Presentation. They are advised to seek their own professional advice on the legal, financial and taxation consequences of making any acquisition of shares in the Company.

The information contained in this Presentation is selective and is subject to updating, expansion, completion, revision, amendment and verification.

Actual results may differ significantly from those set forth in this Presentation. Specifically, the financial information contained in this Presentation is unaudited and subject to completion of the Company's financial closing procedures, final adjustments and other developments. Actual results may differ from the announced estimates. In addition, any forward-looking statements in the Presentation involve certain risks and uncertainties that are subject to change based on various factors, many of which are beyond the Company's control. The Company does not intend to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable laws.

PHC investor presentation July 2021

DISCLAIMER

No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company, or any of its respective Directors, officers, partners, employees, agents, advisers, affiliates, representatives or any other person as to the accuracy or completeness of the information or opinions contained in this Presentation and to the fullest extent permitted by law no responsibility or liability is accepted by any of them for any such information or opinions or for any errors, omissions, misstatements, negligence or otherwise for any other communication written or otherwise or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this Presentation or its contents otherwise in connection with the subject matter of this Presentation or any transaction.

Furthermore, the Company does not undertake or agree to any obligation to update or correct this Presentation, or to provide any recipient with access to any further information. Notwithstanding the foregoing, nothing in this paragraph shall limit or exclude liability for any undertaking, representation, warranty or other assurance made fraudulently.

In the interests of providing information regarding the Company, the Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements appear in a number of places throughout the Presentation and can be identified by the use of forward-looking terminology, including the terms "believes", "envisages", "estimates", "anticipates", "projects", "expects", "potential", "intends", "may", "will", "could", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, financial condition, plans, performance, results of operation, liquidity, prospects, objectives, goals, strategies, future events or intentions. You should not rely upon forward-looking statements except as statements of the Company's present intention and of the Company's present expectations. These forward-looking statements that are not historical facts and speak only as of the date of the Presentation. The Company's expected results may not be achieved and actual results may differ materially from its expectations.

By attending this Presentation and/or accepting a copy of this document, you agree to be bound by the foregoing limitations and, in particular, will be taken to have represented, warranted and undertaken that you have read and agree to comply with the contents of this notice including without limitation the obligation to use this Presentation and its contents only for the intended purpose set out above.

EXECUTIVE SUMMARY

COST-EFFECTIVE PRODUCTS FOR SUSTAINABLE AGRICULTURE:

- Agriculture shifting to more sustainability
 Global demand for biological solutions growing at >16% pa
- PHC's products are both highly cost-effective and sustainable - Awarded the LSE's Green Economy Mark: June 2021

EXISTING COMMERCIAL BUSINESS:

- Proven products, grower ROI typically 6 14x
- Revenue poised to accelerate; profitable and cash generative

Est. 30m	2x sales growth 2020	70% GM	CASH
Hectares Market access	US & Brazil in-market sales	Harpin $\alpha\beta$ in 2020	GENERATIVE

NEXT GENERATION TECHNOLOGY: PRETEC – 'VACCINES FOR PLANTS':

- Lower cost, higher potency, greater stability and ease of use
- Outstanding benefits to growers; potentially disruptive platform technology; >\$20M invested since 2012
- Targeting markets with \$5bn value; first launch planned for H2 2021

PLANT HEALTH CARE – AT AN INFLECTION POINT





HIGHLIGHTS OF H1 TRADING STATEMENT

FINANCIAL

- Revenue +13% to \$3.5m (H1 20:\$3.1m)
- Cash burn \$1.5 Million ¹ (H1 20: \$2.1m)
- Cash reserves \$11.1 Million ²

COMMERCIAL

- Harpin $\alpha\beta$ growth 26%
- Continued in-market sales growth in USA
- Sales in Europe +76%
- Brazil and Mexico held back by drought and Covid-19

PRE*TEC*

- Saori[™] launch in Brazil on track
- USA progressing to launches in 2022 and 2023
- Progress with toll manufacturing

ON TRACK TO DELIVER EXPECTATIONS AND PLANS

- 1. Cash used in operations
- 2. Cash reserves as of 30th June, 2021



COMMERCIAL BUSINESS: STRONG IN-MARKET REVENUE GROWTH IN USA

1. US CORN

- Stronger, taller corn; yield +3 5% at \$3 cost per acre
- Continued strong sales growth in H1 2021, on plan
- Market share approaching 1%; \$5m opportunity ¹


2. SPECIALITY CROPS USA

- Strong spring sales by Wilbur Ellis, on-ground sales tracking above plan
- \$10m pa opportunity through Wilbur Ellis²


Note: Sales ex PHC in the USA occur mainly in H2



Acres treated with Harpin $\alpha\beta$ in US corn 2019-20, 2021 YTD



In-market sales (oz.) of Harpin $\alpha\beta$ in US specialty crops 2019-20, 2021 YTD



PRODUCT ADOPTION ACCELERATING IN VERY LARGE MARKETS

- 1. Based on 92 million acres of US corn, 5% market share would equate to \$5M in potential sales at \$1 per acre ex PHC
- 2. Based on 1% share of the \$1 billion West Coast specialty crop protection market, would equate to PHC revenue of \$10m



1. EUROPE

- Spain/Portugal sales H1 increased 69% driven increased sales in citrus
- Sales to UK potatoes nearly doubled in 2020; continued growth trend in 2021
- UK amenity sales return from Covid-19 effects

2. BRAZIL SUGAR CANE

- Outstanding product benefits: Yield increase >23%; ROI >14x
- Q2 sales affected by drought and Covid-19
- Drought reinforced product benefits; \$15m sales opportunity ¹

3. MEXICO

- H1 2021 sales \$1.3m (vs \$1.4m 2020); third party products 82% of sales
- Low prices of export vegetables challenged revenue in H2 2021
- Currency volatility hit Gross Margin; moving to US\$ pricing from July 2021

Outstanding benefits of H2Copla under drought conditions 2021



Coplacana Sales Hectares LTM 2019 – YTD 2021



OUTSTANDING EUROPE MARKET GROWTH

1. \$15m sales opportunity (based on achieving 10% share of 10m Ha market, at \$18 per Ha ex PHC)



PRETEC: UPDATE ON SAORI[™] BRAZIL LAUNCH PLANS

PRODUCT PERFORMANCE

- Saori[™] treated soy is more vigorous, resists disease
- Potential to reduce fungicide use (\$2.5bn grower spend)
- Average yield increase 4%, worth \$80/Ha to grower



Conventional treatment



With Saori[™] seed treatment, soy plants are healthier & more vigorous, promising greater yield

PRODUCT POSITIONING

- Protects plant against disease
- Maintains healthier crop throughout season
- Sustainable 'green' product; reducing need for use of agrochemicals
- Significant increase in yield; strong ROI




LAUNCH PLANNING

- Strong endorsement from >16 Technical Advisors who trialled Saori in 2020/21 crop
- Encouraging customer reaction in market research
- Small scale launch in 2021; focus on early adopters
- Product awareness campaign under way; hiring field staff
- Initial sale through seed multipliers
- Potential for single national partner

SAORI[™] – *'LOOKING AFTER YOUR SOY WHEN YOU ARE NOT THERE'*



PRETEC: USA LAUNCH PLAN



Update on JDA with Wilbur Ellis

- Field trials in progress in multiple crops; first results promising:
 - Positive results reported from PHC279 on potatoes
 - Very strong nematode control in tomatoes and cucurbits with PHC949; comparable to chemical standard
 - Expecting results for PHC404 initiated in Q4
- On track for first sales of PHC279 in Q4 2022 and PHC 949 in Q4 2023, subject to achieving regulatory approvals

Submit for registration

Target registration date / Approved




PROGRESSING TOWARDS US LAUNCHES IN LARGE MARKETS



H1 2021 - P&L FINANCIAL SUMMARY

	HY 2021 \$000	HY 2020 \$000
Revenue	\$3,499	\$3,100
Gross margin	\$1,956	\$1,814
Margin percentage	56%	59%
Cash operating expenses	\$4,241	\$3,650
Adjusted LBITDA *	(\$2,285)	(\$1,836)
Translational (gain)/loss **	\$(423)	\$1,988
Other non-cash expenses	\$468	\$371
Operating loss ***	(\$2,330)	(\$4,195)

- Revenue increased 13%
- Harpin $\alpha\beta$ revenue increased 26% to \$2.4m
- Gross Margin 56% (H1 HY20: 59%). The decrease is mainly currency effect in Mexico
- Cash operating expenses increased to drive commercial sales and PRE*tec* product launches
- Cash used in operations \$1.5m (HY20: \$2.1m)
- Translational gains/(losses) are non-cash items



* - Adjusted LBITDA defined as loss before interest, tax, depreciation, amortisation and share-based payments and intercompany foreign exchange.

** - Translational gains and loss are based on the value of Sterling loans from our UK subsidiary and fluctuate based on the value of the Pound.

*** - Operating loss includes the effect of translational gains and losses.

ROBUST REVENUE GROWTH



H1 2021 - BALANCE SHEET FINANCIAL SUMMARY

	HY 2021 \$000	FY 2020 \$000
Non-current assets	\$3,154	\$3,144
Inventory	\$3,077	\$3,567
Receivables	\$2,405	\$3,029
Cash and equivalents	\$11,104	\$4,149
Total assets	\$19,740	\$13,889
Payables/accrued exp	\$1,698	\$2,118
Borrowings (leases)	\$1,063	\$1,209
Total liabilities	\$2,761	\$3,327
Total equity	\$16,979	\$10,562

- Inventory progressively reduced over last 18 months
- Receivables decreased \$0.6m from YE 2020
- Working capital decreased \$0.4m or 7% to \$4.6m since YE 2020 (FY 2020: \$5.0m)
- Successfully raised \$9.1m (net of costs) in March 2021
- Cash and equivalents: \$11.1m (FY20: \$4.1m)
- Per IFRS 16 guidance, all leases are included in the balance sheet as borrowings.

STRONG BALANCE SHEET – FOCUSED ON CASH MANAGEMENT



PHC LEADERSHIP TEAM



- DR CHRIS RICHARDS Chief Executive Officer
- Joined PHC in 2012 as Non-Executive Chairman, assuming the role of CEOin 2017
- Over 35 years of management experience
- Previously employed at Syngenta in various senior roles and Arysta LifeScience where he was CEO and Non-Executive Chairman



- Joined in Sept 2013
- Drove re-structuring and cost reduction in 2014
- >25 years financial management experience
- CPA; IFRS and GAAP experience
- Held numerous senior financial and accounting roles in private and publicly listed retail, life sciences and technology companies



JEFF TWEEDY Chief Operations Officer

- Joined Oct 2017; appointed COO in 2018
- Leads all Commercial activities and PREtec launches
- >28 years experience in sales and business development in US and internationally
- Held senior commercial North America and Global roles in Syngenta, Arysta LifeScience, Horizon Ag



MARK TURNER VP Corporate and Business Development

JEFE HOVEY

Chief Financial Officer

- Joined Feb 2018
- Leads business development, licensing and legal
- >20 years experience with strategic alliances and licensing
- Held senior roles at Bayer Crop Science, University of North Carolina, developing and managing global licensing in and out
- Juris Doctor degree and admitted to practice in North Carolina



DR ZHONGMIN WEI Chief Science Officer, VP of R&D

- Joined in 2007
- Drives R&D and product manufacturing development
- Globally recognised for discovery of Harpin $\alpha\beta$ technology as a Post-Doctoral Associate at Cornell
- Winner of Green Presidential Award in 2001
- Led development of Harpin αβ products since 1992
- >25 years developing the synthesis of proteins and peptides
- Inventor on 60+ issued & pending patents



DR PATRICK DOYLE VP Product Development & Regulatory

- Joined June 2021
- Leads product development, regulatory and portfolio management
- 29 years experiences in R&D, regulatory, product development
- Held senior roles in Novartis AG, Syngenta and Plant Response Inc in USA, Canada and Europe

MILESTONES 2021 - 22

COMMERCIAL

- Deliver continued product adoption in three core markets
- Sign up a major new distributor in Europe in 2021
- Deliver revenue growth above sector average of 16+%
- Consistent profit and cash generation

PRE*TEC*

- Launch Saori[™] in Brazil Q3 2021
- Submit PHC949 to EPA in 2021
- Achieve PHC279 registration in USA H2 2022
- Progress JDA with Wilbur Ellis®
- Pursue further JDAs for PREtec
- Appoint toll manufacturer for PHC279 in 2021
- Strengthen peptide IP and formulation development
- Commence PRE*tec* development in Europe


GROUP

- Tracking to Group cash positive
- Explore opportunities from consolidation in the sector

FOCUSSED ON DELIVERY

SHARE METRICS

PLANT HEALTH CARE PLC	AIM: PHC
Share price*	£0.13
Market cap*	£30,071,000
Total shares outstanding**	302,387,482
Stock options [*] (subject to various performance conditions such as share price hurdles)	22,843,302
Total fully diluted shares [*]	325,230,784
52-week range*	£0.082-£0.184



* As of 16 July 2021.

** As of 30 June 2021

*** Excludes stock options held by management and Directors.

Source: London Stock Exchange.

MAJOR SHAREHOLDERS**

Ospraie AG Science	64,154,361	21.22%
Mr. Richard I Griffiths	60,000,000	19.84%
Lombard Odier	27,091,302	8.96%
Janus Henderson	18,214,286	6.02%
Boulder River Capital Corp	15,365,253	5.08%
Management, Directors and related parties***	5,030,032	2.00%

IR contacts:

Plant Health Care plc (AIM:PHC) Katrina Perez

2626 Glenwood Avenue	Vo
Suite 350	+4
Raleigh, NC27608	<u>kp</u>

ox Markets 44 0 7881 622 830 perez@voxmarkets.co.uk

USA